CX3CL1 and metastatic neoplasm: By univariable analysis, the expression status of CX3CL1 was significantly associated with tumor stage [odds ratio (OR)=2.55, 95% confidence interval (95%CI): 1.36-4.76, P=0.003], tumor size (OR=2.06, 95%CI: 1.10-3.86, P=0.025), tumor grade (OR=1.91, 95%CI: 1.02-3.55, P=0.043), disease recurrence (OR=2.05, 95%CI: 1.08-3.88, P=0.029), metastatic disease (OR=3.98, 95%CI: 1.95-8.13, P<0.001), Ki67 expression (OR=1.02, 95%CI: 1.01-1.04, P=0.002) and mortality (OR=4.90, 95%CI: 2.53-9.47, P<0.001, Table S1).